SCHEMBL2003164

SCHEMBL2003164

Cc1c(C(=O)c2nc(-c3ccncc3)no2)c2ccccc2n1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPT P10636 5/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX12 P18054 1/20 0.42
TP53 P04637 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
POLB P06746 1/20 0.41
TSHR P16473 3/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
NFKB1 P19838 1/20 0.40
CASP3 P42574 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2007446 0.94 LMNA (0.44) LMNASMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2006152 0.92 LMNA (0.43) LMNASMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2008177 0.92 TP53 (0.47) LMNASMN1; SMN2MAPTTP53RXFP1
SCHEMBL2004477 0.91 LMNA (0.41) LMNASMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2008018 0.91 GSK3B (0.44) LMNASMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2004316 0.90 LMNA (0.43) LMNASMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2005858 0.89 PLA2G2A (0.44) LMNASMN1; SMN2MAPTALDH1A1TP53
SCHEMBL2002603 0.88 MAPT (0.40) LMNASMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2006155 0.88 LMNA (0.40) LMNASMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2005482 0.87 L3MBTL1 (0.42) LMNASMN1; SMN2MAPTALDH1A1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 LMNA 3450/4885SMN1; SMN2 3581/4885MAPT 997/4885
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT LMNA 4536/4885SMN1; SMN2 4663/4885MAPT 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.